Far Infrared Therapy and Psoriasis / Psoriatic Arthritis
A Mechanistic Review with Explicit Separation from UVB Phototherapy
Overview
Psoriasis and psoriatic arthritis (PsA) present a specific communication risk for far infrared (FIR) therapy: patients are appropriately familiar with light-based treatment (UVB, PUVA) as an established psoriasis therapy, which creates a plausible but incorrect inference that FIR — also “light-based” in consumer framing — operates similarly or offers comparable benefit.
It does not. No controlled trial has evaluated FIR specifically as a treatment for psoriasis or PsA. This review separates the two modalities explicitly, presents the mechanism-transferred rationale for FIR at the appropriate evidentiary level, and flags the unverifiable claims practitioners are likely to encounter from patients.
The key distinction: Far infrared sauna use is not equivalent to UVB or PUVA phototherapy and should not be presented as a replacement for established psoriasis or PsA care.
FIR Is Mechanistically Distinct from UVB/PUVA Phototherapy
UVB phototherapy (280–315 nm) is an evidence-based psoriasis treatment working through direct photochemical effects on epidermal keratinocyte proliferation and local immune modulation. PUVA combines UVA (315–400 nm) with a photosensitizing psoralen. Both operate in the ultraviolet band through photochemical mechanisms.
Far infrared (4–14 µm) occupies a different wavelength range and operates through thermal/vibrational tissue interaction, not the ultraviolet photochemical mechanisms described above. It does not replicate the keratinocyte-modulating mechanism that makes UVB effective, and should not be presented to patients as an alternative or equivalent light-based treatment.
Mechanistic Rationale for FIR
Non-specific to psoriasis and psoriatic arthritis.
NRF2/HO-1 and Inflammatory Signaling
FIR-driven HO-1 induction via the NRF2/ARE pathway restrains NF-κB-dependent inflammatory signaling (Lin 2008, ATVB), shown mechanism-specific and heat-independent in a controlled trial (Bagabir et al. 2025, Free Radic Biol Med).
Direct gene-expression data in an adjuvant-induced arthritis model demonstrate FIR downregulation of NF-κB, MAPK, and PI3K-Akt signaling (Chen et al. 2022, J Adv Res) — pathways centrally implicated in both psoriatic skin inflammation and psoriatic joint disease. None of this has been tested in a psoriasis or PsA population directly.
Adjacent Spondyloarthropathy Data
PsA belongs to the spondyloarthropathy family alongside ankylosing spondylitis (AS), sharing overlapping inflammatory pathophysiology and, in a subset of patients, HLA-B27 association.
A pilot study found infrared sauna produced statistically significant short-term improvement in pain and stiffness in AS patients with no exacerbation of disease activity ( Oosterveld et al. 2009, Clin Rheumatol, PMID 18685882 ). This is the most directly relevant adjacent-condition data available, though it was not conducted in PsA patients and should be represented as such.
Keep the population distinction clear: Findings in ankylosing spondylitis do not establish a treatment benefit for psoriatic arthritis.
Correcting Marketing Attribution
Practitioner Advisory
Claims circulating in consumer content that could not be verified:
- Vendor content reporting specific figures, such as “47% pain reduction” attributed to “the landmark 2009 study,” conflates and inflates the actual Oosterveld 2009 findings, which reported statistically significant but unquantified-by-percentage improvement, no PsA cohort, and did not measure IL-6/TNF-α percentage changes as claimed.
- Testimonial claims of rapid, complete psoriasis clearance, such as “gone in less than a month,” circulating in patient forums and vendor content are anecdotal, uncontrolled, and should not be represented as expected outcomes.
- No verifiable trial supports FIR as a direct psoriasis skin-clearing intervention. Practitioners should expect patients to arrive with these claims and should be prepared to redirect to the actual, more modest evidence base above.
Safety Considerations
Clinical Cautions
- Heat may aggravate symptoms in some patients, while skin trauma can trigger new psoriasis lesions through the Koebner phenomenon. Response to heat exposure is patient-variable and should not be assumed beneficial.
- Systemic PsA therapy — including TNF inhibitors, IL-17/IL-23 inhibitors, and methotrexate — warrants general infection-risk awareness in shared thermal environments, consistent with guidance for other autoimmune conditions in this series.
- FIR must not be positioned as a substitute for phototherapy, topical, or systemic psoriasis/PsA treatment. It is, at most, a general supportive adjunct with no disease-modifying evidence.
Evidence Grading Summary
| Domain | Mechanism Evidence | Human Evidence | Tier |
|---|---|---|---|
| Skin clearance / plaque reduction | None specific | None — no controlled trials identified | Absent |
| Inflammatory gene expression | Strong (AIA model, direct) | Not tested in psoriasis/PsA | Mechanistic Only |
| Joint pain/stiffness (spondyloarthropathy) | N/A | Positive in AS (Oosterveld 2009); not PsA-specific | Preliminary, Adjacent Population |
| Comparability to UVB/PUVA phototherapy | None — distinct EM band and mechanism | Not applicable | Mechanism Mismatch |
On smaller screens, swipe horizontally to view the full table.
Clinical Positioning
FIR therapy has no established evidence base for psoriasis skin clearance and must be clearly distinguished from UVB/PUVA phototherapy in any patient conversation.
For PsA joint symptoms specifically, the AS pilot data offer modest, honestly labeled adjacent-condition support for general symptom relief alongside — never in place of — standard dermatologic and rheumatologic management.
Practitioners should be prepared to correct inflated pain-reduction and skin-clearance claims patients may bring from consumer or testimonial sources.
Supportive use does not establish skin clearance, disease modification, or equivalence to medical phototherapy.
References
Lin, C.C. et al. (2008). HO-1 induction via NRF2/ARE pathway. ATVB.
Bagabir, R. et al. (2025). Heat-controlled trial of far infrared exposure and NRF2-mediated vascular signaling. Free Radic Biol Med.
Chen, Y. et al. (2022). Far-infrared radiation modulates inflammatory gene expression in adjuvant-induced arthritis. J Adv Res, 38, 107–118.
Oosterveld, F.G. et al. (2009). Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis: a pilot study. Clin Rheumatol. PMID 18685882.
American Academy of Dermatology. Psoriasis: phototherapy treatment guidelines (UVB/PUVA mechanism reference).
